Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma
Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma
The major aim of this research is to assess the feasibility, safety and effectiveness of CD19
 CAR-T Cell Therapy for Relapsed/ Refractory Acute Lymphoblastic Leukemia/ B cell Lymphoma
 patients who have applied it.
Inclusion Criteria:

 1. Subjects or their legal guardians participate in this experiment voluntarily and
 informed consent form must be signed

 2. In accordance with National Comprehensive Cancer Network (NCCN) ALL Guidelines for
 Patients (2016, v.1) and CD19+B-ALL/B cell lymphoma patients diagnosed by histology

 3. In accordance with r/r CD19+ B-ALL/B cell lymphoma diagnosis, including any of the
 following situations:

 1. Getting through 2 treatments of standard chemotherapy with CR not yet obtained

 2. Reach CR for the first inducement, but CR lasts for ≦12 months

 3. r/r CD19+ B-ALL/B cell lymphoma for no positive effect after first or repeated
 remedial treatment

 4. ≧2 times of recurrence

 4. Remedial chemotherapy is not used within 4 weeks before cell therapy

 5. Immunosuppressive drug is not used within 4 weeks before cell therapy, including but
 not limited to systemic hormone therapy

 6. Antibody drug treatment is not received within 2 weeks before cell therapy

 7. Normal cardiac motion shown by echocardiography, left ventricular ejection fraction
 (LVEF) ≥50%, with no pericardial effusion and severe symptoms of cardiac arrhythmia

 8. No pulmonary active infection is found, with normal pulmonary function and indoor air
 SaO2 ≧92%

 9. No contraindications for leukapheresis

 10. Expected survival >3 months

 11. Grade 0 or 1 of ECOG performance status

 Exclusion Criteria:

 1. Pregnant and breastfeeding women

 2. Uncontrolled active infection

 3. Uncontrolled infectious disease is diagnosed, such as HIV, syphilis, hepatitis A,
 hepatitis B, hepatitis C and E.

 4. Patients who have used a large amount of glucocorticoid or other immunosuppressive
 drugs within 4 weeks

 5. Stage II-IV Acute/chronic general graft versus host disease

 6. Gene therapy has been undergone in the past